CPT September 2022

Clin Pharmacol Ther. 2022;112:461-484. Regulation of drug transport proteins-From mechanisms to clinical impact: A white paper on behalf of the International Transporter Consortium. Brouwer KLR, Evers R, Hayden E, Hu S, Li CY, Meyer Zu Schwabedissen HE, Neuhoff S, Oswald S, Piquette-Miller M, Saran C, Sjöstedt N, Sprowl JA, Stahl SH, Yue W. PubMed

Clin Pharmacol Ther. 2022;112:501-526.Clinical implications of altered drug transporter abundance/function and PBPK modeling in specific populations: An ITC Perspective. Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder JS, Mukherjee D, Taskar K, Varma MVS, Zhang X, Yang X, Galetin A. PubMed

Clin Pharmacol Ther. 2022;112:423-426. More than pharmacokinetics: Transporters in clinical pharmacology. Giacomini KM, Huang SM. PubMed

Clin Pharmacol Ther. 2022;112:540-561. New and emerging research on Solute Carrier and ATP Binding Cassette Transporters in drug discovery and development: Outlook from the International Transporter Consortium. Giacomini KM, Yee SW, Koleske ML, Zou L, Matsson P, Chen EC, Kroetz DL, Miller MA, Gozalpour E, Chu X. PubMed

Clin Pharmacol Ther. 2022;112:653-664. Blockade of Organic Anion Transport in humans After treatment with the drug Probenecid leads to major metabolic alterations in plasma and urine. Granados JC, Bhatnagar V, Nigam SK. PubMed

Clin Pharmacol Ther. 2022;112:527-539. Transporters and toxicity: Insights from the International Transporter Consortium Workshop. Hafey MJ, Aleksunes LM, Bridges CC, Brouwer KR, Chien HC, Leslie EM, Hu S, Li Y, Shen J, Sparreboom A, Sprowl J, Tweedie D, Lai Y. PubMed

Clin Pharmacol Ther. 2022;112:562-572. Challenges and opportunities for improved Drug-Drug Interaction predictions for renal OCT2 and MATE1/2-K transporters. Krishnan S, Ramsden D, Ferguson D, Stahl SH, Wang J, McGinnity DF, Hariparsad N. PubMed

Clin Pharmacol Ther. 2022;112:627-634. Exposure of Fexofenadine, but not Pseudoephedrine, is markedly decreased by Green Tea extract in healthy volunteers. Misaka S, Ono Y, Taudte RV, Hoier E, Ogata H, Ono T, König J, Watanabe H, Fromm MF, Shimomura K. PubMed

Clin Pharmacol Ther. 2022;112:676-686. Genomewide Association Study of Simvastatin pharmacokinetics. Mykkänen AJH, Taskinen S, Neuvonen M, Paile-Hyvärinen M, Tarkiainen EK, Lilius T, Tapaninen T, Backman JT, Tornio A, Niemi M. PubMed

Clin Pharmacol Ther. 2022;112:593-604. Prediction of hepatobiliary clearances and hepatic concentrations of transported drugs in humans using Rosuvastatin as a model drug. Storelli F, Li CY, Sachar M, Kumar V, Heyward S, Sáfár Z, Kis E, Unadkat JD. PubMed

Clin Pharmacol Ther. 2022;112:615-626. Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease. Takita H, Scotcher D, Chu X, Yee KL, Ogungbenro K, Galetin A. PubMed

Clin Pharmacol Ther. 2022;112:643-652. Effect of chronic kidney disease on the renal secretion via Organic Anion Transporters 1/3: Implications for physiologically-based pharmacokinetic modeling and dose adjustment. Tan SPF, Scotcher D, Rostami-Hodjegan A, Galetin A. PubMed

Clin Pharmacol Ther. 2022;112:573-592. Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: An International Transporter Consortium Perspective. Taskar KS, Yang X, Neuhoff S, Patel M, Yoshida K, Paine MF, Brouwer KLR, Chu X, Sugiyama Y, Cook J, Polli JW, Hanna I, Lai Y, Zamek-Gliszczynski M. PubMed

Clin Pharmacol Ther. 2022;112:605-614. Effect of a Ketohexokinase inhibitor (PF-06835919) on in vivo OATP1B activity: Integrative risk assessment using endogenous biomarker and a probe drug. Tess DA, Kimoto E, King-Ahmad A, Vourvahis M, Rodrigues AD, Bergman A, Qui R, Somayaji V, Weng Y, Fonseca KR, Litchfield J, Varma MVS. PubMed

Clin Pharmacol Ther. 2022;112:446-449. Clinical relevance of Organic Anion Transporting Polypeptide 1B-mediated hepatic uptake for high-permeability drugs: A perspective. Varma MVS. PubMed

Clin Pharmacol Ther. 2022;112:699-710. Quantitative proteomics of hepatic drug-metabolizing enzymes and transporters in patients with colorectal cancer metastasis.  Vasilogianni AM, Al-Majdoub ZM, Achour B, Annie Peters S, Barber J, Rostami-Hodjegan A. PubMed

Clin Pharmacol Ther. 2022;112:665-675. Evaluation of the effect of Abrocitinib on drug transporters by integrated use of probe drugs and endogenous biomarkers. Vourvahis M, Byon W, Chang C, Le V, Diehl A, Graham D, Tripathy S, Raha N, Luo L, Mathialagan S, Dowty M, Rodrigues AD, Malhotra B. PubMed

Clin Pharmacol Ther. 2022;112:439-442. Accelerating SLC transporter research: Streamlining knowledge and validated tools. Wiedmer T, Ingles-Prieto A, Goldmann U, Steppan CM, Superti-Furga G; RESOLUTE, REsolution consortia. PubMed

Clin Pharmacol Ther. 2022;112:450-452. Current perspective on residual knowledge gaps in the assessment of transporter-mediated drug interactions. Yang X, Reynolds K, Madabushi R, Huang SM. PubMed

Clin Pharmacol Ther. 2022;112:635-642. Trends in FDA transporter-based post-marketing requirements and commitments over the last decade. Younis IR, Manchandani P, Hassan HE, Qosa H. PubMed

Clin Pharmacol Ther. 2022;112:485-500. Transporters in drug development: International Transporter Consortium update on emerging Transporters of Clinical Importance. Zamek-Gliszczynski MJ, Sangha V, Shen H, Feng B, Wittwer MB, Varma MVS, Liang X, Sugiyama Y, Zhang L, Bendayan R. PubMed